Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-523 in relapsed or refractory NSCLC
NCT00112060Phase 2Withdrawn
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of talotrexin in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Planned start Apr 2008; status: withdrawn.
02
Drugs
talotrexin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00112060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112060.